According to the 2013 National HealthInterview Survey, the most recent report used by the Centers for Disease Control and Prevention (CDC), only 29.6 percent of adults ages 18 to 48 receive the flu vaccine, and that number increases to 46.5 percent for adults ages 50 to 64and 67.9 percent for adults over 68.
Nationwide, nearly 11.7 million consumers selected or were automatically re-enrolled in health insurance coverage through the Health Insurance Marketplace as of Feb. 22, according to a report by the U.S. Department of Health and Human Services.
Octapharma USA has launched the Octapharma Co-Pay Assistance Program available to von Willebrand’s disease patients who are currently receiving Wilate or have a prescription to begin therapy.
Baxter International spun off its Baxter BioScience global biopharmaceutical business into Baxalta, which will focus on developing new treatments for people with orphan diseases and underserved conditions.
The Biosimilars Forum was launched by 11 of the leading biosimilar developers in the U.S.
A new study has found that many influenza-positive patients, including those with high-risk conditions, go undiagnosed in favor of a diagnosis of bacterial disease coinfection.
Results from a human trial of GlaxoSmithKline’s Ebola vaccine show it is safe and generates an immune response.
Plasma Tech Biopharmaceuticals has developed a new and innovative method to extract plasma proteins from pooled human plasma samples.
The Medicare Rights Center has released a new Medicare Snapshot: Stories from the Helpline that addresses Medicare enrollment pitfalls and outlines needed improvements.
The U.S. Department of Health and Human Services’ Office of the Assistant Secretary for Preparedness and Response (ASPR) has awarded approximately $12 million to BioCryst Pharmaceuticals for the advanced development of a promising experimental drug for Ebola.
Grifols has made a major equity investment in Alkahest to work together to develop novel plasma-based products for the treatment of cognitive decline in aging and disorders of the central nervous system.
The Centers for Medicare and Medicaid Services (CMS) plans to begin paying for biosimilars through its Part B,Part D and state coverage policies by this summer, according to a question-and-answer document released in April.
